Deepthi Jayawardene

1.4k total citations
30 papers, 1.1k citations indexed

About

Deepthi Jayawardene is a scholar working on Hematology, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Deepthi Jayawardene has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Epidemiology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Deepthi Jayawardene's work include Blood groups and transfusion (8 papers), Platelet Disorders and Treatments (7 papers) and Pneumonia and Respiratory Infections (6 papers). Deepthi Jayawardene is often cited by papers focused on Blood groups and transfusion (8 papers), Platelet Disorders and Treatments (7 papers) and Pneumonia and Respiratory Infections (6 papers). Deepthi Jayawardene collaborates with scholars based in United States, United Kingdom and Germany. Deepthi Jayawardene's co-authors include Helen E. Heslop, Robert A. Krance, Beate Schmöele-Thoma, William C. Gruber, Emilio A. Emini, Deo Kumar Srivastava, Dhiraj Kumar Srivastava, Sean Phipps, C C Patrick and Daniel A. Scott and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Geriatrics Society.

In The Last Decade

Deepthi Jayawardene

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deepthi Jayawardene United States	17	502	284	204	166	164	30	1.1k
Joanne Reekie Denmark	24	577 1.1×	129 0.5×	64 0.3×	27 0.2×	132 0.8×	63	1.5k
Vatsla Dadhwal India	20	222 0.4×	375 1.3×	65 0.3×	55 0.3×	349 2.1×	139	1.4k
Bosny Pierre‐Louis United States	17	243 0.5×	150 0.5×	35 0.2×	197 1.2×	222 1.4×	40	1.0k
Jerome Kopelman United States	14	545 1.1×	313 1.1×	40 0.2×	55 0.3×	157 1.0×	52	1.1k
Miguela A. Caniza United States	21	431 0.9×	283 1.0×	38 0.2×	55 0.3×	315 1.9×	72	1.3k
Lawrence Muhangi United Kingdom	23	244 0.5×	380 1.3×	67 0.3×	26 0.2×	246 1.5×	34	1.3k
S. Cameron United Kingdom	23	945 1.9×	43 0.2×	109 0.5×	90 0.5×	162 1.0×	43	1.4k
Paul A. Hensleigh United States	25	716 1.4×	548 1.9×	73 0.4×	109 0.7×	259 1.6×	53	1.6k
Florence Veber France	18	489 1.0×	94 0.3×	153 0.8×	81 0.5×	71 0.4×	48	1.6k
Tamara Rakusan United States	21	420 0.8×	86 0.3×	58 0.3×	36 0.2×	125 0.8×	38	1.3k

Countries citing papers authored by Deepthi Jayawardene

Since Specialization

Citations

This map shows the geographic impact of Deepthi Jayawardene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepthi Jayawardene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepthi Jayawardene more than expected).

Fields of papers citing papers by Deepthi Jayawardene

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepthi Jayawardene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepthi Jayawardene. The network helps show where Deepthi Jayawardene may publish in the future.

Co-authorship network of co-authors of Deepthi Jayawardene

This figure shows the co-authorship network connecting the top 25 collaborators of Deepthi Jayawardene. A scholar is included among the top collaborators of Deepthi Jayawardene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepthi Jayawardene. Deepthi Jayawardene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuter, David J., Quentin A. Hill, Bruno Fattizzo, Deepthi Jayawardene, & Ahmed Daak. (2025). Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design. Blood. 146(Supplement 1). 1123–1123.

Fattizzo, Bruno, Henrik Frederiksen, Alessandro Lucchesi, et al.. (2025). Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up. Blood. 146(Supplement 1). 4655–4655.

Cooper, Nichola, David J. Kuter, Henrik Frederiksen, et al.. (2024). Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study. Blood. 144(Supplement 1). 3836–3836. 6 indexed citations

Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2024). Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension. EClinicalMedicine. 74. 102732–102732. 1 indexed citations

Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2024). Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. EClinicalMedicine. 74. 102733–102733. 5 indexed citations

Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2023). Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Advances. 7(19). 5890–5897. 8 indexed citations

Röth, Alexander, Wilma Barcellini, Shirley D’Sa, et al.. (2023). Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. American Journal of Hematology. 98(8). 1246–1253. 16 indexed citations

Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2023). P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY. HemaSphere. 7(S3). e83270db–e83270db. 1 indexed citations

Juergens, Christine, Pierre J.T. De Villiers, Keymanthri Moodley, et al.. (2014). Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults. Human Vaccines & Immunotherapeutics. 10(5). 1343–1353. 31 indexed citations

10.

Jackson, Lisa A., Alejandra Gurtman, Martin van Cleeff, et al.. (2013). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 31(35). 3577–3584. 172 indexed citations

11.

Schwarz, Tino F., Karlis Pauksens, Christine Juergens, et al.. (2013). Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23-Valent Pneumococcal Polysaccharide Vaccine: An Open-Label Trial. 3(4). 123–129. 6 indexed citations

12.

Frenck, Robert W., Alejandra Gurtman, John Rubino, et al.. (2012). Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. Clinical and Vaccine Immunology. 19(8). 1296–1303. 61 indexed citations

13.

Schwarz, Tino F., H. C. Rümke, C. Juergens, et al.. (2011). A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 29(32). 5195–5202. 83 indexed citations

14.

Schwarz, Tino F., H. C. Rümke, C. Juergens, et al.. (2009). Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults. Journal of the American Geriatrics Society. 57.

15.

Ellis, Charles N., et al.. (2007). Placebo Response in Two Long-Term Randomized Psoriasis Studies that were Negative for Rosiglitazone. American Journal of Clinical Dermatology. 8(2). 93–102. 33 indexed citations

16.

Hudson, Melissa M., Vida L. Tyc, Deepthi Jayawardene, et al.. (1999). Feasibility of implementing health promotion interventions to improve health-related quality of life. International Journal of Cancer. 83(S12). 138–142. 30 indexed citations

17.

Phipps, Sean, et al.. (1999). Assessment of health-related quality of life in acute in-patient settings: Use of the BASES instrument in children undergoing bone marrow transplantation. International Journal of Cancer. 83(S12). 18–24. 67 indexed citations

18.

Heslop, Helen E., et al.. (1999). Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplantation. 23(3). 277–282. 195 indexed citations

19.

Hinds, Pamela S., et al.. (1998). Testing the stress‐response sequence model in paediatric oncology nursing. Journal of Advanced Nursing. 28(5). 1146–1157. 28 indexed citations

20.

Tyc, Vida L., Raymond K. Mulhern, Deepthi Jayawardene, & Diane L. Fairclough. (1995). Chemotherapy-induced nausea and emesis in pediatric cancer patients: An analysis of coping strategies. Journal of Pain and Symptom Management. 10(5). 338–347. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact